Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Cash & Equivalents (2016 - 2025)

Conmed (CNMD) has disclosed Cash & Equivalents for 16 consecutive years, with $40.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 66.88% year-over-year to $40.8 million, compared with a TTM value of $40.8 million through Dec 2025, up 66.88%, and an annual FY2025 reading of $40.8 million, up 66.88% over the prior year.
  • Cash & Equivalents was $40.8 million for Q4 2025 at Conmed, up from $38.9 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $53.2 million in Q2 2022 and bottomed at $20.8 million in Q4 2021.
  • Average Cash & Equivalents over 5 years is $33.0 million, with a median of $32.4 million recorded in 2021.
  • The sharpest move saw Cash & Equivalents plummeted 47.61% in 2023, then skyrocketed 66.88% in 2025.
  • Year by year, Cash & Equivalents stood at $20.8 million in 2021, then surged by 38.83% to $28.9 million in 2022, then decreased by 16.05% to $24.3 million in 2023, then grew by 0.67% to $24.5 million in 2024, then surged by 66.88% to $40.8 million in 2025.
  • Business Quant data shows Cash & Equivalents for CNMD at $40.8 million in Q4 2025, $38.9 million in Q3 2025, and $33.9 million in Q2 2025.